FDA局长周二接受采访时指责药品价格高的企业，制药商与药店经理谈判回扣，以确保他们的处方在药店出售。雇主通常会利用这些回扣来降低整个员工的保费，而不是给那些支付药品费用的患者。
Food and Drug Administration Commissioner Scott Gottlieb in an interview Tuesday blamed high drug prices, in part, on the "wacky" system where pharmaceutical companies discount their drugs but patients don't see those savings.
美国食品药品监督管理局（Food and Drug Administration）局长戈特利布周二接受采访时指责药品价格高企，部分原因是制药公司对药品打折，但病人看不到这些折扣。
Drugmakers negotiate discounts, known as rebates, with pharmacy benefit managers in order to secure a spot on their formularies. Employers typically use these rebates to lower premiums for employees across the board rather than giving them to the patients who are paying for the drugs.
制药商与药店利益经理谈判折扣，称为回扣，以确保他们的处方。雇主通常会利用这些回扣来降低整个员工的保费，而不是给那些支付药品费用的患者。
"[Patients are] spending money to subsidize everyone else's premium," Gottlieb said in an interview with CNBC's "Squawk Box" on Tuesday. "The sick people are helping to subsidize the healthy people. That's not how insurance is supposed to work. So we've got a wacky system where the discounts aren't flowing to the people."
Gottlieb 在接受 CNBC 的“ SquawkBox ”采访时说：“（病人）正在花钱补贴其他人的保险费。”“生病的人正在帮助补贴健康的人。这不是保险应该如何运作的。所以我们有一个古怪的系统，折扣不会流向人们。”
Lawmakers are set to grill executives from seven drugmakers — AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi — today at Senate Finance Committee hearing. They are sure to ask about high list prices. Drug companies say these prices are merely starting points and that few people really pay these.
国会议员今天将在参议院财政委员会听证会上质询来自七家制药公司——艾伯维（AbbVie）、阿斯利康（AstraZeneca）、百时美施贵宝（Bristol-Myers Squibb）、 Johnson & Johnson 、默克（Merck）、辉瑞（Pfizer）和赛诺菲（Sanofi）——的高管。他们肯定会问到高价的问题.制药公司说，这些价格仅仅是起点，很少有人真正支付这些费用。
Rebates are a favorite target of pharmaceutical companies, who say pharmaceutical benefit managers extract huge discounts but keep them for themselves instead of sharing the savings with patients. The PBMs say it's drugmakers alone who set high prices.
回扣是制药公司最喜欢的目标，他们说，医药福利管理者为自己获取巨大的折扣，而不是与患者分享储蓄。PBM 表示，只有制药商才能开出高价。
